Corient Private Wealth LP Has $57.94 Million Stake in CME Group Inc. $CME

Corient Private Wealth LP increased its stake in shares of CME Group Inc. (NASDAQ:CME) by 66.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 262,371 shares of the financial services provider’s stock after buying an additional 104,730 shares during the quarter. Corient Private Wealth LP’s holdings in CME Group were worth $57,940,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Whipplewood Advisors LLC increased its stake in CME Group by 2,075.0% in the 1st quarter. Whipplewood Advisors LLC now owns 87 shares of the financial services provider’s stock valued at $26,000 after buying an additional 83 shares during the period. Elkhorn Partners Limited Partnership acquired a new stake in shares of CME Group during the 4th quarter valued at $27,000. Hilton Head Capital Partners LLC purchased a new position in shares of CME Group during the 4th quarter valued at $28,000. Main Street Group LTD acquired a new position in shares of CME Group in the first quarter worth $32,000. Finally, Bayban purchased a new stake in shares of CME Group during the fourth quarter worth $31,000. 87.75% of the stock is owned by hedge funds and other institutional investors.

CME Group Stock Up 0.5%

CME stock opened at $275.54 on Friday. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. CME Group Inc. has a 1 year low of $218.31 and a 1 year high of $329.16. The company has a fifty day simple moving average of $263.56 and a 200 day simple moving average of $277.42. The firm has a market cap of $99.08 billion, a PE ratio of 23.37, a PEG ratio of 3.26 and a beta of 0.24.

CME Group (NASDAQ:CME) last posted its earnings results on Wednesday, July 22nd. The financial services provider reported $2.99 EPS for the quarter, topping the consensus estimate of $2.91 by $0.08. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.68 billion. CME Group had a net margin of 63.30% and a return on equity of 15.60%. The business’s quarterly revenue was up .8% on a year-over-year basis. During the same period in the prior year, the business posted $2.96 earnings per share. Sell-side analysts anticipate that CME Group Inc. will post 12.27 EPS for the current fiscal year.

CME Group Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Wednesday, September 9th. CME Group’s dividend payout ratio is 44.11%.

Insider Activity

In related news, Director William R. Shepard bought 325 shares of CME Group stock in a transaction that occurred on Thursday, June 25th. The stock was purchased at an average cost of $230.57 per share, for a total transaction of $74,935.25. Following the acquisition, the director owned 260,442 shares in the company, valued at $60,050,111.94. This trade represents a 0.12% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Terrence A. Duffy sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $274.44, for a total value of $4,116,600.00. Following the sale, the chief executive officer directly owned 40,630 shares of the company’s stock, valued at $11,150,497.20. The trade was a 26.96% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on CME. UBS Group reduced their price objective on CME Group from $310.00 to $260.00 and set a “buy” rating for the company in a research report on Monday, July 6th. The Goldman Sachs Group dropped their target price on CME Group from $267.00 to $245.00 and set a “sell” rating on the stock in a research report on Tuesday, June 30th. Morgan Stanley raised their price target on CME Group from $324.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft lowered CME Group from a “buy” rating to a “hold” rating and reduced their price target for the company from $286.00 to $270.00 in a report on Wednesday, August 19th. Finally, Keefe, Bruyette & Woods raised CME Group from a “market perform” rating to an “outperform” rating and set a $305.00 price target for the company in a research note on Thursday, June 18th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $289.75.

CME Group Profile

CME Group Inc operates global derivatives marketplaces that provide trading, clearing and settlement services for a broad range of financial and commodity products. Its exchange platforms enable participants to manage risk, discover prices and gain exposure to asset classes including interest rates, equity indexes, foreign exchange, energy, metals, agricultural commodities and digital assets.

The company’s principal marketplaces include CME, CBOT, NYMEX and COMEX. Products are offered through futures and options contracts, with electronic trading available through CME Globex as well as exchange-based and privately negotiated transactions.